Akili

Akili Interactive Labs is a digital therapeutics company for autism. Its leading products are AKL-T01 and AKL-T02, which target attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), respectively. The series of products selectively activate specific cognitive neural systems in the brain by providing sensory and motor stimulation to treat areas of cognitive impairment in the brain. Akili Interactive Labs has also developed personalized digital therapies that directly improve cognitive impairments. This form of digital therapy does not require drug intervention; patients can complete treatment by engaging in action video games. Akili Interactive Labs is advancing a series of projects based on its patented technology platform to treat cognitive deficits and symptoms related to neurological and psychiatric disorders. Akili Interactive Labs combines world-class neuroscience with cutting-edge technology and video game entertainment to achieve breakthroughs in autism treatment. Its digital medicine is delivered not through pills or injections but via a proprietary and engaging video gaming experience. The digital therapies provided by Akili Interactive Labs are developed based on years of neuroscience knowledge and built through proprietary technology to treat cognitive impairments in specific areas of the brain.